Disclosures for "Natalizumab Discontinuation in Pregnancy: Evaluating Relapse Risk in MS Patients After the Second Trimester"
Dr. Mohajery has nothing to disclose.
Author has nothing to disclose
Ms. Brewi has nothing to disclose.